The global antiviral drugs market size is estimated to grow from USD 69 billion in 2025 to reach USD 74 billion in 2026 and USD 127 billion by 2035, representing a higher CAGR of 6.1% during the forecast period 2026 to 2035. According to the National Institute for Health’s reports, around 52 million (33%) deaths are caused by infectious diseases annually. COVID-19 is one of the latest examples of an infectious disease that caused 3 million deaths worldwide. Before COVID-19, Human Immunodeficie...

The global clinical trial patient recruitment services market, valued at USD 11.8 billion in 2025, is projected to reach USD 12.8 billion in 2026 and USD 26.2 billion by 2035, with a 8.3% CAGR during the forecast period 2026 to 2035. Studies suggest that around 40% of the total investment made for the development of a drug candidate is dedicated to clinical trials. However, around 80% of the clinical trials are delayed due to insufficient patient recruitment. Further, retaining patients is also...

The mitochondrial disease therapies market, valued at USD 518 million in 2025 to reach USD 660 million in 2026 and USD 1,817 million by 2030, with a higher CAGR of 28.8% during the forecast period, 2026 to 2030. Mitochondrial diseases are characterized by chronic, genetic and progressive medical symptoms that arise due to inherited or spontaneous mutations in mitochondrial DNA (a small, circular, double-stranded with ~16,500 base pairs that exists outside of the nucleus). It is worth highlighti...

The cytotoxic drugs and HPAPI manufacturing market, valued at USD 13.98 billion in 2025, is projected to grow to USD 15.59 billion in 2026 and USD 46.41 billion by 2035, representing a CAGR of 12.89% during the forecast period 2026 to 2035. Around 40% of approved drugs in the market are classified as highly potent. Of these, 60% of the approved HPAPI-based drugs are used for cancer treatment, owing to their ability to exhibit highly effective therapeutic responses with minimal dosage.

The global T-cell therapy market, valued at USD 6.5 billion in 2025, is projected to grow to USD 8.1 billion in 2026 and USD 20.9 billion by 2035, representing a CAGR of 11.2% during the forecast period 2026 to 2035. According to NIH, in 2024, around 2 million people are estimated to be diagnosed with various types of cancer in the U.S. alone. The US FDA approved multiple T cell therapies targeting cancer (in reverse chronological order), such as Obecabtagene autoleucel / Aucatzyl (relapsed or r...

The global site management organization market, valued at USD 12.4 billion in 2025, is projected to reach USD 13.6 billion in 2026 and USD 31.6 billion by 2035, with a 9.8% CAGR during the forecast period 2026 to 2035. Studies suggest that around 40% of the total investment made for the development of drug candidate is dedicated to clinical trials; this is equivalent to an expenditure of USD 78 billion annually. Currently, around 250 companies claim to be actively providing SMO services to drug...

The global healthcare simulators market size, valued at USD 3.04 billion in 2024, is projected to reach USD 3.61 billion in 2025 and USD 14.49 billion by 2035, representing a CAGR of 14.9% during the forecast period. It is worth mentioning that the need for healthcare simulators has significantly increased due to the growing medical education systems where practitioners / students can improve their skills using these innovative technologies. Driven by the ongoing demand, several industrial playe...

Currently, more than 40 industrial and non-industrial players are engaged in the development of drugs for polycystic ovary syndrome. Notably, 70% of the industrial players are very large firms. It is worth noting that these industrial players are widely emphasizing symptomatic treatment of polycystic ovary syndrome. However, with widespread demand companies like AstraZeneca are currently evaluating clinical drugs to cure PCOS condition.

The global TIL therapy market, valued at USD 0.3 billion in 2025, is projected to reach USD 0.6 billion in 2026 and USD 4.2 billion by 2035, with a 23.4% CAGR during the forecast period 2026 to 2035. TILs are a heterogeneous population of mononuclear lymphocytes that comprise of T-cells, B-cells, Natural killer cell therapies and macrophages isolated from the tumor. Notably, over 75 TIL cell therapy are being evaluated across different stages of preclinical / clinical development, either as mono...

It is important to highlight here that the USFDA has also approved numerous cancer biosimilar products for cancer treatment, such as bevacizumab, rituximab and trastuzumab. Notably, biosimilars of bevacizumab (Avastin®) are presently available with brand name, Alymsys®, Avzivi®, Jobevne™, Mvasi®, Vegzelma® and Zirabev®. The market for oncology biosimilars in Asia-Pacific is expected to grow at a higher CAGR during the forecast period. Notably, the rising prevalence of cancer is expected...

In Asia-Pacific, the market for non-invasive fat reduction is expected to register a higher CAGR during the forecast period. This lucrative growth is likely to be fueled by the heightened social media influence and adoption of aesthetic procedures for body contouring and fat reduction. Additionally, the companies like AbbVie, and VLCC are expanding their clinical proven technologies such as CoolSculpting Elite and VLCC Lipo-1060 latest laser technology for far reduction, in Asian countries, such...

The TCR therapy market, valued at USD 442 million in 2025, is projected to reach USD 533 million in 2026 and USD 1,563 million by 2035, with a 12.7% CAGR during the forecast period 2026 to 2035, mainly driven by the need for targeted cancer treatment for solid tumors. Presently, more than 100 industry and non-industry players across the globe are evaluating the potential of over 190 T cell receptor based immunotherapies for the treatment of various oncological and non-oncological disorders. Furt...

The CRISPR based genome editing service market, valued at USD 2.1 billion in 2025, is projected to reach USD 2.7 billion in 2026 and USD 5.9 billion by 2030, with a 22.1% CAGR during the forecast period 2026 to 2030. The 1970s witnessed the introduction of one of the most revolutionary advances in biotechnology, when Hamilton Smith purified the 1st site-specific restriction enzyme, called Hind II. Soon after, in the 1980s, the US FDA approved the world

The global drug bioavailability enhancement market, valued at USD 3.6 billion in 2025, is projected to reach USD 4.0 billion in 2026 and USD 10.2 billion by 2035, with a 11.1% CAGR during the forecast period 2026 to 2035. A search study found that most candidates fail during the early phases of clinical trials. The study also underscored that almost 90% of New Chemical Entities (NCEs) in pre-clinical and clinical stages face solubility or permeability challenges. Consequently, there has been a n...

Several industrial players are currently focusing on the development of advanced PCSK9 inhibitors and exploring more therapeutic potential. For instance, in June 2025, Merck (US) announced positive results of enlicitide decanoate, an investigation oral PCSK9 from the first two of three phase III clinical trials evaluating safety and efficacy. This drug is being evaluated under clinical trial for the treatment of adults with hyperlipidemia on lipid-lowering therapies. These positive outcomes and...

Currently, the global market for glycobiology is valued at USD 1.95 billion in 2025 and is poised to reach USD 6.77 billion by 2035, representing a CAGR of 13.2% during the forecast period. This lucrative growth is likely to be the result of increasing research on glycomics.To leverage the competitive edge, several industrial players are driving innovations, investments and partnerships in this field. For instance, in December 2024, GlycoNet (global leader in glycomics research and innovations)...

The global long acting drugs market, valued at USD 1.29 billion in 2025, is projected to reach USD 1.55 billion in 2026 and USD 4.62 billion by 2035, with a 12.9% CAGR during the forecast period 2026 to 2035. Many stakeholders have been making consolidated efforts to forge alliance with other industry / non-industry players for technology licensing, product development and manufacturing purposes. It is worth highlighting that over 90 strategic partnerships have been inked since 2018 in this mark...

The global lyophilization services market, valued at USD 3.0 billion in 2025, is projected to reach USD 3.2 billion in 2026 and USD 4.7 billion by 2035, with a 4.3% CAGR during the forecast period 2026 to 2035. Antibodies market segment holds the largest share of the market and are poised to capture 52% of the overall revenue share by 2035.

Recent research published by researchers at Mount Sinai in January 2025, led by Josep M. Llovet, MD, PhD, Professor of Medicine (Liver Diseases) at the Icahn School of Medicine at Mount Sinai have made a breakthrough in the treatment of hepatocellular carcinoma with combination approach. Under Phase III clinical study, “LEAP-012: Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma,” has show...

The global targeted drug delivery device market size is projected to grow from $427 Million in 2026 to $2,153 Million by 2035, representing a CAGR of 19.7% during the forecast period. The new research study consists of industry trends, detailed market analysis, clinical trial analysis, likely drug candidates and market impact analysis, along with the market forecast and opportunity analysis. Currently, there are more than 1,000 cell and gene therapies under development, most of which are being d...